Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JQ1D
|
|||
| Former ID |
DIB020820
|
|||
| Drug Name |
Ro 41-5253
|
|||
| Synonyms |
Ro-415253; Ro415253; LG629
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C28H36O5S
|
|||
| Canonical SMILES |
CCCCCCCOC1=CC2=C(C=C1C(=CC3=CC=C(C=C3)C(=O)O)C)C(CCS2(=O)=O)(C)C
|
|||
| InChI |
1S/C28H36O5S/c1-5-6-7-8-9-15-33-25-19-26-24(28(3,4)14-16-34(26,31)32)18-23(25)20(2)17-21-10-12-22(13-11-21)27(29)30/h10-13,17-19H,5-9,14-16H2,1-4H3,(H,29,30)/b20-17+
|
|||
| InChIKey |
JEIWQRITHXYGIF-LVZFUZTISA-N
|
|||
| CAS Number |
CAS 144092-31-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:90706
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor alpha (RARA) | Target Info | Antagonist | [2] |
| KEGG Pathway | Pathways in cancer | |||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Pathway Interaction Database | Retinoic acid receptors-mediated signaling | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Adipogenesis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2642). | |||
| REF 2 | A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7129-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.